Patients with prediabetes, obesity, and schizophrenia who received semaglutide for 30 weeks have significant improvements in glycemic, weight, and quality of life (QOL) outcomes, according to results of a double-blind, placebo-controlled trial published in JAMA Psychiatry. Patients with schizophrenia often have unhealthy behaviors, including poor diet quality, inactivity, smoking, and excessive alcohol and/or drug use. The primary outcome was the change in HbA 1c . Participants receiving semaglutide vs placebo also had greater increases in:Physical component of QOL (MD, 3.75 points; P =.001);Amylase levels (MD, 4.98 U/L; P =.003);High-density lipoprotein cholesterol (MD, 10.81 mg/dL; P =.007); and,Creatinine levels (MD, 0.04 mg/dL; P =.01). “[I]n patients with schizophrenia, prediabetes, and obesity, once-weekly semaglutide injections, up to 1.0 mg/week, were safe and effective,” the study authors concluded.